IPN01203 / Ipsen - LARVOL DELTA

Development of IPN01203, a dual T cell agonist activating Vβ6/Vβ10 TCR-expressing T cells (AACR 2026) - "Abstract is embargoed at this time."

Oncology

CLIN-01203-450: A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies (clinicaltrialsregister.eu) - P1/2 | N=38 | Not yet recruiting | Sponsor: Ipsen Pharma

Checkpoint inhibition • First-in-human • New P1/2 trial • Oncology • Solid Tumor

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies (clinicaltrials.gov) - P1/2 | N=102 | Recruiting | Sponsor: Ipsen | Not yet recruiting ➔ Recruiting

Checkpoint inhibition • Enrollment open • First-in-human • Oncology • Solid Tumor

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies (clinicaltrials.gov) - P1/2 | N=102 | Not yet recruiting | Sponsor: Ipsen

Checkpoint inhibition • First-in-human • New P1/2 trial • Oncology • Solid Tumor